To compare and analyze the safety and efficacy of 1 470 nm laser en bloc resection of bladder tumor (1 470 nm-EBRBT) and traditional transurethral resection of bladder tumor (TURBT) in the treatment of non-muscular invasive bladder cancer (NMIBC).

A total of 100 patients with NMIBC (T_a or T₁) diagnosed by cystoscopy and pathology from January 2017 to January 2020 were selected as subjects. The patients were randomly divided into observation group (n=50) and control group (n=50). The observation group was treated with 1 470 nm-EBRBT and the control group with TURBT. All patients were followed up for (31±4) months with gemcitabine intravesical instillation chemotherapy, secondary electroresection and regular cystoscopy. The safety, efficacy, pathological results and recurrence-free survival rate were compared between the two groups.

The operative complications in the observation group were less than those in the control group, the catheter indwelling time and hospitalization in the observation group were shorter than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the pathological type and grade of the first resected specimens between the two groups (P>0.05). The proportion of detrusor in the first resected pathological specimens in observation group was higher than that in control group, and the difference was statistically significant (P<0.05). The tumor residual rate in observation group was lower than that in control group, and the difference was not statistically significant (P>0.05). There was no significant difference in recurrence-free survival curve and cox regression hazard ratio Exp(B) between the two groups (P>0.05).

Compared with traditional TURBT, 1 470 nm-EBRBT has the advantages of accurate surgical effect, complete pathological specimens, less possibility of tumor residue, fewer complications, shorter indwelling catheter time and shorter hospitalization time for NMIBC patients.